Specialty Oncology
-
Featured
Mass General Offers Novel, Kidney-saving Urothelial Cancer Treatment
Mitomycin chemoablation with a mitomycin gel, a novel treatment offered in the Department of Urology at Massachusetts General Hospital, can avoid the need for surgical removal of the kidney and ureter in patients with upper tract urothelial cancer.
-
Featured
Using Machine Learning to Predict Prostate Cancer Progression During Active Surveillance
Madhur Nayan, MDCM, PhD, and Adam S. Feldman, MD, MPH, and colleagues created the first machine learning models for predicting prostate cancer progression during active surveillance and found they outperformed traditional logistic regression.
-
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution
David M. Langenau, PhD, Marcela V. Maus, MD, PhD, and colleagues created a new line of transparent zebrafish that allow single-cell imaging of tumor cell killing during immunotherapy with CAR T-cells, bispecific T-cell engagers and antibody–peptide epitope conjugates in a wide range of cancers.
-
Improved Coping Explains Benefits of Integrated Palliative Care for Patients With Acute Myeloid Leukemia
Improvement of coping strategies was a key mechanism of the benefits of integrated palliative care for patients with acute myeloid leukemia who were hospitalized for intensive chemotherapy, Ashley M. Nelson, PhD, and colleagues conclude based on a secondary analysis of a randomized controlled trial.
-
Trial Co-led by Mass General Leads to Oral Drug Approval for Red Blood Cell Disorder
A Phase 3 clinical trial conducted by Massachusetts General Hospital researchers and an international team of colleagues has led to the FDA's approval of an oral drug for treatment of adults with pyruvate kinase deficiency, a rare red blood cell disorder.
-
ASCENT Trial: Sacituzumab Govitecan Has Survival Benefit in Metastatic Triple-negative Breast Cancer
Aditya Bardia, MD, MPH, is the first author of the report of the phase 3 ASCENT trial, which showed a significant survival benefit for sacituzumab govitecan compared with standard chemotherapy in patients with relapsed/refractory metastatic triple-negative breast cancer.
Mass General Cancer Center Contributors
-
Andrew T. Chan, MD, MPH
Professor of Medicine, Harvard Medical School, Director for Cancer Epidemiology, Mass General Cancer Center, Chief, Clinical and Translational Epidemiology Unit, Department of Medicine
Recent Article
Sulfur Microbial Diet Linked to Precursor of Early-onset Colorectal Cancer
-
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Improved Coping Explains Benefits of Integrated Palliative Care for Patients With Acute Myeloid Leukemia
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
MRI–Ultrasound Fusion–Targeted Transperineal Prostate Biopsy Complements Standard Biopsy for Detecting Perineural Invasion
-
Joseph H. Schwab, MD, MS
Chief, Orthopaedic Spine Surgery, Director, Spine Oncology & Co-Director, Stephen L. Harris Chordoma Center, Associate Professor of Orthopaedic Surgery, Harvard Medical School
Recent Article
Predictive Utility of Natural Language Processing Algorithms for Posterior Lumbar Fusion Patients
-
Keith T. Flaherty, MD
Director of Clinical Research, Mass General Cancer Center, Professor of Medicine, Harvard Medical School
Recent Article
Capivasertib Shows Promise Against Refractory AKT-mutated Tumors
-
Keyan Salari, MD, PhD
Urologic Surgeon, Department of Urology, Massachusetts General Hospital, Urologic Oncologist, Mass General Cancer Center, Co-Director, Prostate Cancer Genetics Program
Recent Article
Active Surveillance for Prostate Cancer
-
Marcela G. del Carmen, MD
Chief Medical Officer, Massachusetts General Physicians Organization and Massachusetts General Hospital, Gynecologic Oncologist, Department of Obstetrics and Gynecology, Clinician, Center for Gynecologic Oncology, Mass General Cancer Center
Recent Article
U.S. COVID-19 Test Results Strongly Correlate with Race/Ethnicity, Income
-
Marcela V. Maus, MD, PhD
Director, Cellular Immunotherapy Program, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Novel Zebrafish Model Allows Assessment of T-Cell–based Immunotherapies at Single-Cell Resolution -
Nir Hacohen, PhD
Director, MGH Center for Cancer Immunology
Center for Cancer Research , Professor of Medicine, Harvard Medical School, Senior Member, Broad InstituteRecent Article
Immune Cell Hubs Interact with Malignant Cells in Human Colorectal Cancer
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology
Recent Article
Immunotherapies to Treat Glioblastoma
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
